Arrowhead Pharmaceuticals (ARWR)
(Delayed Data from NSDQ)
$19.62 USD
+0.20 (1.03%)
Updated Sep 26, 2024 03:59 PM ET
After-Market: $19.61 -0.01 (-0.05%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Arrowhead Pharmaceuticals, Inc. [ARWR]
Reports for Purchase
Showing records 1 - 20 ( 95 total )
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
Pulmonary Franchise Open to Partnering; Advances in Phase 1/2; TRiM Platform Takes RNAi Beyond the Liver
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
Muscle-Targeted Franchise Advances in Phase 1/2
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
Plozasiran Positive Phase 3 Data Positions Potential First Drug Approval in 2025; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
ARO-RAGE Clears Clinical Hurdle at ATS, Supporting Program Advancement in Asthma; Preclinical Data Impresses; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
F2Q24 Results; Expect Positive Data Readouts on Underappreciated Cardiometabolic and Pulmonary Programs
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
Encouraging Plozasiran Phase 2b Data Support Moving to Phase 3 Program
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
Hepatitis B Breakthrough Boom: Navigating a $450-$500 Billion Frontier
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
F1Q24 Results; Trims Pipeline to Focus on Liver and Lung Programs; Multiple Readouts on Track in 2024; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
IND Filing For Complement Mediated Kidney Disease Reinforces "20 in ''25" Strategic Goal; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
FY2023 Results; 20 in ''25 Strategy on Track; Pulmonary Platform Clears Safety Hurdle; Nears Multiple Readouts; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for ARWR 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
Unprecedented Results at AHA Place Cardio-Metabolic Pipeline on Track for Blockbuster Status
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
F3Q23 Results; Pipeline Progressing on Track; Nearing Key Pulmonary Preclinical Chronic Tox Data Readouts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
Fazirsiran Appears on Track For Positive Outcome in Phase 3 REDWOOD Alpha One Program; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
RD Day Takeaways: 20 in ''25 Goal on Track; CNS, Pulmonary and Liver-Targeted Programs Progressing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
ARO-ANG3 Clears Initial Hurdle in Phase 2 Trial in Patients with HoFH; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
F2Q23 Results; Expects to Unveil Plethora of Data at June 1 RD Day; Multiple Late Stage Programs Progessing on Track
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
Phase 1/2 ARO-RAGE Program Clears First Hurdle; Next Update Expected at R&D Day on June 1; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
F1Q23 Earnings; Reports Broad Pipeline Progress; Attractively Valued Ahead of Myriad Pipeline Updates Expected in 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
Partnered Fazirsiran Advancing to Phase 3 in Alpha One; Plethora of Pipeline Updates on Track; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P